Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.73 +2.44 (+2.70%)
Streaming Delayed Price Updated: 12:46 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
BioNTech Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
4 Analysts Have This To Say About BioNTech
Via Benzinga
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. 
Via Stocktwits
BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Peering Into BioNTech's Recent Short Interest
Via Benzinga
Why BioNTech (BNTX) Shares Are Volatile Today
Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations. 
Via Benzinga
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025. 
Via Benzinga
Exposures COVID-19
BioNTech Surpasses Q4 Revenue Estimates
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue. 
Via The Motley Fool
US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory
U.S. stock futures declined on Monday after a small bout of relief on Friday as indices neared the correction zone. 
Via Benzinga
Topics Government
Exposures Political
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Earnings Scheduled For March 10, 2025
Via Benzinga
Dow Gains Over 200 Points But Records Weekly Loss: Fear Among Investors Eases But Greed Index Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
BioNTech, Oracle And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Nasdaq Falls Into Correction As Tariffs Roil Wall Street: What's Moving Markets Friday?
All three major indices were red in Friday’s midday trading, with the S&P 500 and Nasdaq 100 down 1% and 1.24%, respectively, and on track for their worst weeks since September 2024. 
Via Benzinga
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine
BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with regulators on next steps. 
Via Benzinga
Exposures Product Safety
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
From BioNTech SE
Via GlobeNewswire
Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination. 
Via Investor's Business Daily
Pfizer Edges Higher As Covid Sales Decline, But Still Beat Expectations
Pfizer stock rose moderately early Tuesday on the back of its quarterly beat. 
Via Investor's Business Daily
Exposures COVID-19
BioNTech Completes Acquisition of Biotheus
From BioNTech SE
Via GlobeNewswire
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
Exposures COVID-19
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.